Carlyle's Rubenstein champions emerging markets
The bloom has faded from the rose in emerging markets in recent years, which means it is an opportune time to invest in these geographies, according to David Rubenstein (pictured), co-founder and co-executive chairman of The Carlyle Group.
“Emerging markets not as much in favor as a few years ago,” he told the International Finance Corporation’s (IFC) global private equity conference in Washington DC. “That’s the time to invest....
More on GPs
Latest News
Chinese O2O language training provider files for US IPO
Meten International Education Group, a Chinese online-to-offline (O2O) English language training provider that mainly caters to adult students, has filed for a US IPO. DG Capital is the primary PE investor in the company.
Singapore's VisVires launches $150m food tech fund
VisVires New Protein, a Singapore-based VC firm specializing in food technology, has launched its second fund with a target of $150 million. Fund I closed at $40 million in 2016.
China’s Allist Pharmaceuticals raises $171m Series A
Shanghai-based drug developer Allist Pharmaceuticals has raised RMB1.2 billion ($171 million) in a Series A round of funding led by Shiyu Capital. Other participants include Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment.
SBI joins $35m Series B for Japan's Pixie Dust
SBI Investment, the VC arm of Japan’s SBI Holdings, has joined a JPY3.8 billion $35 million Series B round for Pixie Dust Technologies, a local company developing novel uses for ultrasonic waves.